AbbVie Inc. · Q3 2025
ReportedOct 31, 2025
Period endedSep 30, 2025
Rule of 40+51
The quarter in short
Revenue $15.78B, up 9.1% year over year and 2.3% on the quarter. EPS $0.10, down 88.6% year over year and 80.8% on the quarter. Free cash flow $6.64B, up 27.8% year over year and 36.0% on the quarter. Rule of 40 score +51.
Reported this quarter
Revenue
$15.78B
QoQ +2.3%
YoY +9.1%
EPS
$0.10
QoQ −80.8%
YoY −88.6%
Free Cash Flow
$6.64B
QoQ +36.0%
YoY +27.8%
Gross Margin
66.4%
QoQ −5.4 pp
YoY −4.5 pp
FCF Margin
42.1%
QoQ +10.4 pp
YoY +6.2 pp
P/E Ratio
172.8
QoQ +100.2%
YoY +165.0%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1551152.
HTML
8-K results announcement
Filed Oct 31, 2025
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
468 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Sep 30, 2025, filed Nov 4, 2025
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure ABBV has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q3 2025, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings